Nothing to be too fussed about. Adverse reactions would be the scary one. I recall there was a long list of criteria to be met to be recruited. Importantly they seem to have just about caught up after a slow start.
ha-irinotecan phase iii clinical trial update , page-4
Add TSN (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $1.409M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
| TSN (ASX) Chart |
Day chart unavailable